Clinical Trials and Progress in Metastatic Colon Cancer

Kabir Mody, Tanios Bekaii-Saab

Research output: Contribution to journalReview article

16 Scopus citations


Colorectal cancer (CRC) is a leading cause of cancer-related deaths worldwide but associated mortality has declined in recent decades. Genomic profiling of the disease has resulted in the definition of subsets of patients—for example, KRAS, NRAS, or BRAF mutated; Her2 amplified; and mismatch repair deficient—which has enabled personalization of therapeutic decision making. These subsets are guiding drug development and combination therapy approaches using both targeted therapies and immunotherapies. Further refinement based on molecular discoveries and the emergence of newer technologies to enable new discoveries allow for great optimism for the future on behalf of patients with colon cancer.

Original languageEnglish (US)
Pages (from-to)349-365
Number of pages17
JournalSurgical Oncology Clinics of North America
Issue number2
StatePublished - Apr 1 2018



  • BRAF
  • Clinical trials
  • Colorectal cancer
  • Her2
  • Immunotherapy
  • KRAS

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this